bicalutamide teva 50 mg
teva sweden ab - bikalutamid - tablett, filmdrasjert - 50 mg
nebido 1000 mg/4 ml
paranova as (1) - testosteronundekanoat - injeksjonsvæske, oppløsning - 1000 mg/4 ml
casodex 150 mg
laboratoires juvisé pharmaceuticals - bikalutamid - tablett, filmdrasjert - 150 mg
casodex 50 mg
laboratoires juvisé pharmaceuticals - bikalutamid - tablett, filmdrasjert - 50 mg
leuprorelin sandoz 5 mg
sandoz - københavn - leuprorelinacetat - implantat - 5 mg
flutamid orion 250 mg
orion corporation orion pharma - flutamid - tablett - 250 mg
bicalutamide bluefish 50 mg
bluefish pharmaceuticals ab - bikalutamid - tablett, filmdrasjert - 50 mg
bicalutamide teva 150 mg
teva sweden ab - bikalutamid - tablett, filmdrasjert - 150 mg
firmagon
ferring pharmaceuticals a/s - degarelix - prostata neoplasmer - endokrin terapi - firmagon is a gonadotrophin releasing hormone (gnrh) antagonist indicated:- for treatment of adult male patients with advanced hormone-dependent prostate cancer. - for treatment of high-risk localised and locally advanced hormone dependent prostate cancer in combination with radiotherapy. - as neo-adjuvant treatment prior to radiotherapy in patients with high-risk localised or locally advanced hormone dependent prostate cancer.
degarelix accord
accord healthcare s.l.u. - degarelix acetate - prostata neoplasmer - other hormone antagonists and related agents - degarelix accord is a gonadotrophin releasing hormone (gnrh) antagonist indicated:for treatment of adult male patients with advanced hormone-dependent prostate cancer. for treatment of high-risk localised and locally advanced hormone dependent prostate cancer in combination with radiotherapy. as neo-adjuvant treatment prior to radiotherapy in patients with high-risk localised or locally advanced hormone dependent prostate cancer.